FDA accepts Hepion’s IND application for CRV431 to treat Covid-19
In July this year, the company revealed a potential two-pronged strategy for the treatment of Covid-19. First, preclinical cell culture experiments shown CRV431 reduced SARS-CoV-1 production of infectious
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.